Materials and Methods
We identified 78 locally advanced or advanced NSCLC patients with
chronic viral infection treated with PD-1/PD-L1 inhibitors alone or
combined with the chemotherapy/bevacizumab therapy, of whom 60 with
hepatitis B, 2 with hepatitis C, and 16 with syphilis. Objective
response rates were assessed using the RECIST v1.1. Adverse events were
graded following the National Cancer Institute Common Terminology
Criteria for Adverse Events v5.0.